When did OMEGA THERAPEUTICS INC (OMGA) report earnings last quarter?
OMEGA THERAPEUTICS INC (OMGA) last reported earnings on 3/6/2025.
NASDAQ:OMGA • US68217N1054
Past quarterly earnings results for OMEGA THERAPEUTICS INC (OMGA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2024 | -0.30 | -0.28 | -6.31% | 25.00% | 2.612M | 1.265M | 106.48% | 214.32% |
| Q2 2024 | -0.30 | -0.37 | 19.51% | 44.44% | 2.134M | 967.98K | 120.46% | 181.16% |
| Q1 2024 | -0.36 | -0.34 | -5.88% | 28.00% | 2.36M | 1.663M | 41.91% | 357.36% |
| Q4 2023 | -0.37 | -0.46 | 19.12% | 42.19% | 989K | 581.4K | 70.11% | 33.65% |
| Q3 2023 | -0.40 | -0.54 | 25.81% | 25.93% | 831K | 459K | 81.05% | 38.50% |
| Q2 2023 | -0.54 | -0.52 | -4.39% | - | 759K | 459K | 65.36% | 58.13% |
| Q1 2023 | -0.50 | -0.61 | 17.83% | -19.05% | 516K | 263.497K | 95.83% | 91.11% |
| Q4 2022 | -0.64 | -0.64 | 0.40% | -45.45% | 740K | 262.65K | 181.74% | - |
| Q3 2022 | -0.54 | -0.63 | 14.06% | 5.26% | 600K | 103.224K | 481.26% | - |
| Q2 2022 | -0.54 | -0.53 | -2.30% | 83.93% | 480K | 52.53K | 813.76% | - |
| Q1 2022 | -0.42 | -0.58 | 27.44% | - | 270K | - | - | |
| Q4 2021 | -0.44 | -0.54 | 18.61% | - | - | - | ||
| Q3 2021 | -0.57 | -0.49 | -16.42% | - | - | - | ||
| Q2 2021 | -3.36 | -1.23 | -172.24% | - | - | - | ||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
OMEGA THERAPEUTICS INC (OMGA) last reported earnings on 3/6/2025.
OMEGA THERAPEUTICS INC (OMGA) missed EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, OMEGA THERAPEUTICS INC (OMGA) has beaten EPS estimates in 2 out of 4 releases.